Global Cluster Headache Market, by Type (Episodic and Chronic), by Drug Type (Fast-acting Drugs, Long-term Drugs, and Short-term Drugs), by Route of Administration (Oral, Topical, Intravenous, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) was valued at US$ 355.2 Million in 2021 and is projected to exhibit a CAGR of 6.4% during the forecast period (2021-2028).
The increasing approval of novel therapies for the treatment of cluster headache by the U.S. Food and Drug Administration (FDA), is projected to provide a profitable opportunity for industry participants to introduce their novel products. For instance, in April 2017, Electrocore (a neuroscience and technology company), announced that the U.S. FDA approved the use of gammaCore (a non-invasive vagus nerve stimulator) for the acute treatment of pain associated with episodic cluster headache in adult patients. Through the skin, gammaCore sends a mild electrical stimulation to the vagus nerve, which reduces pain.
Global Cluster Headache Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 pandemic has affected various industries globally. The players operating in the global cluster headache market are facing major challenges on various fronts due to the COVID-19 pandemic. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally, as of October 13, 2021, are approximately 238,229,951 confirmed cases with 4,859,277 deaths.
The COVID-19 pandemic caused major disruptions to clinical trial executions in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced disturbances, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, contract research organizations, and other organizations that support drug development shifted to remote working environments.
Browse 44 Market Data Tables and 35 Figures spread through 192 Pages and in-depth TOC on “Global Cluster Headache Market”- Forecast to 2028, Global Cluster Headache Market, by Type (Episodic and Chronic), by Drug Type (Fast-acting Drugs, Long-term Drugs, and Short-term Drugs), by Route of Administration (Oral, Topical, Intravenous, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) – Forecast 2028
To know the latest trends and insights related to Global Cluster Headache Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/cluster-headache-market-4709
The key players operating in the global cluster headache market are focusing on receiving New Drug Application (NDA) for their products by the U.S. FDA to increase their market presence in the global market. For instance, in June 2021, Amneal Pharmaceuticals, Inc., a pharmaceutical company focused on the development, manufacturing, and distribution of drug products, announced that company’s 505(b)(2) New Drug Application for a newly licensed dihydroergotamine (DHE) prefilled syringe autoinjector was accepted by the U.S. FDA, and the business expects a decision for the product approval by the middle of 2022. If approved, Amneal plans to market the product in the second part of 2022. Amneal intends to sell the product exclusively in the U.S.
Key Takeaways of the Global Cluster Headache Market:
- The global cluster headache market is expected to exhibit a CAGR of 6.4% during the forecast period, owing to the increased screen time (which includes television viewing and computer usage). For instance, according to a publication in Medline Plus 2019, most American children spend about three hours a day in front of the television. Together, all types of screen time can be five to seven hours per day. This can increase the risk of cluster headache as well as obesity.
- Among type, episodic is the most common type of CH that occurs regularly between one week and one year. For instance, as per a study published in Plos One Journals in August 2019, data taken from the Korean Cluster Headache Registry (KCHR), revealed that of out of the 250 patients with CH enrolled for the study (a multicenter study of consecutively enrolled patients with CH from 13 university hospitals and two secondary general hospitals from September 2016 to December 2018 found), 176 (70, 4%), 12 (4.8%), and 27 (10.8%) participants were diagnosed with episodic CH, chronic CH and probable CH, respectively.
- Major players operating in the global cluster headache market include Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc, ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc, Allergan plc, Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc.
